Furthermore, more Anti-IFN-γ patients experienced moderate to extreme problems (level 3–5) in the mobility, self-care, usual activities, pain/discomfort and anxiety/depression domains compared to the healthy controls. The gene discussed is IFNG; the disease is depressive symptom measurement.